DOACs Better than Warfarin in Patients with Valvular Atrial Fibrillation, finds study

It was a new-user retrospective propensity score-matched cohort study. Researchers included a total of 56 336 patients with valvular AF who were newly prescribed DOACs or warfarin. They evaluated the U.S.-based commercial health care database from 1 January 2010 to 30 June 2019. The major efficacy outcome assessed was a composite of ischemic stroke or systemic embolism. The major safety outcome assessed was a composite of intracranial or gastrointestinal bleeding.

Key findings of the study were:

• Upon analysis, the researchers found that the use of DOACs (vs warfarin) was associated with a lower risk for ischemic stroke or systemic embolism (hazard ratio [HR], 0.64 ) and major bleeding events (HR, 0.67).
• They noted that the safety and efficacy outcomes remained consistent for apixaban (HRs, 0.54 and 0.5, respectively) and for rivaroxaban it was (HRs, 0.74 and 0.87, respectively).
• However, with dabigatran, they noted that the results were consistent for the major bleeding outcome (HR, 0.81) but not for effectiveness (HR, 1.03).

The authors concluded, "In this comparative effectiveness study using practice-based claims data, patients with valvular AF who were new users of DOACs had lower risks for ischemic stroke or systemic embolism and major bleeding than new users of warfarin. These data may be used to guide risk-benefit discussions regarding anticoagulant choices for patients with valvular AF."

For further information:

https://www.acpjournals.org/doi/10.7326/M20-6194